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Summary and Implications
The objective of this study was to characterize
absorption of colostrum replacer (CR) or supplement (CS)
containing fractions of bovine plasma. Immunoglobulin
concentrate (IGC) was prepared from abattoir blood to a
final purity of approximately 90% IgG. Blood was also
processed to produce a fraction containing elevated
concentrations of IGF-I and TGF-β (GF). Both IGC and GF
were spray-dried and blended with other ingredients to
produce CR (30% IgG) or CS (15% IgG) containing 0 or
5% GF. Forty Holstein bull calves were assigned to one of
five treatments: 1) Pooled colostrum (MC) - 1.9 L of
pooled colostrum at 1 and 8 h of age; 2) Low supplement
(LC) - 1.9 L of CS at 1 and 8 h of age to provide 150 g of
IgG; 3) Low supplement + GF (LG) - 1.9 L of a CS with
GF at 1 and 8 h of age to provide 150 g of IgG; 4) High
supplement (HC) - 1.9 L of CR at 1 h of age to provide 150
g of IgG and 1.9 L of a commercial milk replacer (MR) at 8
h of age; and 5) High supplement + GF (HG) - 1.9 L of a
CR with GF at 1 h of age to provide 150 g of IgG and 1.9
L of a commercial MR at 8 h of age. Apparent efficiency of
IgG absorption was higher for calves fed HC and HG
compared to those fed LC and LG and was lower for calves
fed LG and HG compared to those fed LC and HC. IgG
concentrations at 24 h were highest in calves fed MC
compared to other calves and were higher in calves fed HC
and HG compared to LC and LG. Calves fed LG and HG
had lower IgG concentrations at 24 h of age compared to
those fed LC and HC. Xylose absorption was not influenced
by treatment in calves fed HG, HC, and MC. These results
indicate that 150 g of IgG provided in one dose soon after
birth is superior to 150 g of IgG fed in two doses 7 h apart.
Also, addition of a fraction of bovine plasma containing
elevated concentrations of IGF-I and TGF-β to the CS and
CR formulation decreased IgG absorption in the neonatal
calf.
Introduction
Colostrum is vital to the health and survival of the
neonatal calf, and 18% of dairy cows provide colostrum
yields containing less than 100 g of IgG, the most
commonly recommended amount to prevent failure of
passive transfer (FPT). Colostrum-deprived calves are 50-75
times more likely to die before 21 d of age than colostrum-
fed calves, with most deaths occurring during the first week
of life. Therefore, colostrum supplements (CS) and
colostrum replacers (CR) can be provided when colostrum is
either of poor quality or unavailable. Colostrum
supplements are preparations intended to provide < 100 g of
IgG/dose and are not formulated to replace colostrum. On
the other hand, colostrum replacers contain > 100 g
IgG/dose and usually provide additional nutrients required
by the calf.
The ability to absorb IgG intact across the intestinal
epithelium diminishes rapidly after birth and ceases by
approximately 24 h of age. Current management practices
often include feeding a certain volume of colostrum to
calves at birth and again 12 h later. When the mass of IgG
is held constant, greater amounts are absorbed when the
concentration in the colostrum is higher – for example 1 L
of colostrum containing 100 mg IgG/ml has is absorbed
with greater efficiency than 2 L of colostrum containing 50
mg IgG/ml. Studies in calves comparing colostrum replacer
that provide a similar mass of IgG fed in one or divided
into two feedings are limited.
Colostrum not only provides passive immunity for the
newborn calf, but it can also have profound effects on the
development of the neonatal intestine. Villous
circumference, area, height and height/crypt depth ratio in
the duodenum are higher for calves fed colostrum compared
to colostrum-deprived calves. Calves fed colostrum also
have higher plasma xylose concentrations after oral
administration of xylose compared to calves fed milk
replacer (MR), suggesting enhanced absorptive capabilities
in colostrum fed animals.
Colostrum contains elevated levels of many growth
factors, including insulin-like growth factor-I (IGF-I),
which has been shown to enhance intestinal development in
piglets. Calves fed colostrum have increased xylose uptake
when compared to calves fed formula similar to colostrum
but containing only 15% of the IGF-I content of colostrum.
In contrast, no enhancement of gut development is observed
in colostrum fed calves after oral or subcutaneous injection
of IGF-I. The effect of growth factors on immunoglobulin
absorption has not been characterized.
Therefore, the objectives of this study were two-
fold: (1) to characterize the absorption of colostrum replacer
(CR) or supplement (CS) containing a fraction of bovine
plasma with elevated concentrations of IGF-I and
transforming growth factor-β (TGF-β) and (2) to characterize
the absorption of a similar mass of IgG fed in one feeding
or divided into two feedings.
Procedures
Diet Formulation
     Bovine blood was collected from animals in an USDA
inspected abattoir. Animals were inspected and approved for
human consumption followed by stunning with captive bolt
and exsanguination. Blood was collected into a stainless
steel container treated with anticoagulant. Plasma was
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separated by centrifugation, chilled (approximately 4°C) and
transported to the laboratory. Immunoglobulin G was
fractionated from plasma using a precipitation procedure.
The resulting immunoglobulin concentrate (IGC) contained
nine-times the percentage of IgG in plasma. Bovine plasma
was also processed to produce a fraction containing elevated
concentrations of IGF-1 and TGF-β (GF). Both IGC and
GF were spray-dried and blended with other ingredients
(Table 1) to produce CR (30% IgG) or CS (15% IgG) and
either containing 0 or 5% GF. The CS was formulated to
provide 75 g of IgG/500 g dose; two doses were fed to
provide a total of 150 g IgG. The CR was formulated to
provide 150 g IgG/500 g dose; one dose was fed to provide
150 g IgG.
Maternal colostrum was collected and stored in 5-gallon
buckets prior to feeding. Colostrum was fed within four
hours of collection. Samples colostrum and experimental
diet were analyzed for IgG content and for proximate
nutrients according to AOAC procedures at a commercial
facility (Silliker Inc., Cedar Rapids, IA).
Experimental Procedure
     Holstein bull calves (n = 40) were removed from their
dams immediately after birth and assigned to one of five
treatments: 1) Pooled colostrum (MC) - 1.9 L of pooled
colostrum at 1 and 8 h of age; 2) Low supplement (LC) -
1.9 L of CS at 1 and 8 h of age to provide 150 g of IgG; 3)
Low supplement + GF (LG) - 1.9 L of a CS with GF at 1
and 8 h of age to provide 150 g of IgG; 4) High supplement
(HC) - 1.9 L of CR at 1 h of age to provide 150 g of IgG
and 1.9 L of a commercial MR at 8 h of age; and 5) High
supplement + GF (HG) - 1.9 L of a CR with GF at 1 h of
age to provide 150 g of IgG and 1.9 L of a commercial MR
at 8 h of age. Experimental diets were reconstituted in water
and mixed in a household blender until well blended. The
mixture was then poured into a nipple bottle and offered to
the calf. Amounts not voluntarily consumed were provided
via an esophageal feeder.
At 0 and 24 h of age, blood was collected from all
calves by jugular venipuncture into evacuated tubes
containing EDTA. A small sample of blood was used for
hematocrit determination using a microhematocrit
centrifuge. Plasma was collected by centrifugation and total
protein was determined with a handheld refractometer
(Schuco Clinical Refractometer). Remaining plasma was
frozen (-20°C) for later determination of IgG by
turbidimetric immunoassay.
Xylose Absorption
     Five calves each from the treatment groups HG and MC,
and six calves from group HC were administered an oral
xylose solution (0.5 g d-xylose/kg body weight) at 2 d of
age approximately 4 h after the morning meal. Blood
samples were obtained from each calf via jugular
venipuncture prior to xylose administration and again at 2 h
after xylose ingestion. Plasma was collected by
centrifugation and frozen (-20°C) for later
spectrophotometric analysis.
Statistical Analysis
     Experimental data were analyzed using the general linear
models procedure of SAS. Orthogonal contrasts were used
to test differences between MC and CR, low IgG dose and
high IgG dose, 0 and 5% GF addition, and high IgG dose
with and without GF addition. Chi square analysis was
used to determine differences in FPT. Significance was
declared at P < 0.05 unless otherwise noted.
Results and Discussion
Composition of the experimental CS and CR, as well
as the MR provided to calves on treatment HC and HG, is
provided in Table 2. Crude protein percentage was slightly
higher in HC and HG diets; however, total protein
consumed was similar between treatments since calves on
treatment HC and HG were fed MR at 8 h of age.
Composition of GF is in Table 3. Four calves did not
survive until the 24 h blood sample; data from these calves
were excluded from analyses. Mean BW of calves did not
differ among treatments (Table 4). Frequency of feeding via
esophageal feeder also did not differ among treatments.
     Concentrations of IgG (Table 4) were highest at 24 h of
age in calves fed MC compared to calves in the other four
treatment groups, which is easily attributable to the
difference in IgG intake. Total IgG intake was 282 g for
calves fed MC and 150 g for calves fed all other treatments.
The GF fraction contributed an additional 4 g of IgG.
Concentrations of IgG were higher at 24 h of age in calves
fed HC and HG compared to LC and LG, even though the
total IgG intake was equal between all groups. Apparent
efficiency of IgG absorption (AEA); (Table 4) was also
higher in calves fed HC and HG compared to those fed LC
and LG. These results contradict previous findings that
show no difference in serum IgG concentrations and similar
AEA after feeding calves a large amount at birth or the same
amount divided into two or three feedings. However,
comparisons in previous studies were based on feeding
maternal colostrum, whereas calves in the current study
received CS or CR. The AEA for CR derived from bovine
Ig concentrate has been shown to be higher when fed once
compared to feeding twice after birth 8 h apart. The values
for AEA observed in this trial are similar to those
previously reported for CS and CR prepared from bovine
plasma. However, IgG concentrations were higher in calves
fed the CS and CR formulations than those previously
reported for calves receiving 150 g IgG obtained from
bovine serum.
Calves fed LG and HG also had lower IgG
concentrations at 24 h of age and lower AEA compared to
those fed LC and HC, suggesting that addition of GF to the
CS and CR formulation negatively influenced IgG
absorption. Concentrations of TGF-β and IGF-1, although
concentrated in the serum fraction, were still well below the
concentrations found in bovine colostrum. Values for IGF-I
and TGF-β1 in cow colostrum range from 203-1850 ng/ml
and 12.4-42.6 ng/ml, respectively. Calves fed a bovine
colostral extract that also contained low levels of IGF-I
shiowed increases in intestinal villus circumference and
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villus height and decreased xylose absorption that was
hypothesized to be a result of normal intestinal maturation
but reduced absorptive capacity.
The lack of difference in xylose absorption after
addition of GF also supports previous reports that show no
enhancement of gut development after oral administration of
IGF-I. Xylose absorption was not different between calves
fed either 0 or 5% GF in the current study, however, there
were differences in IgG absorption suggesting a change in
absorptive capacity or in IgG metabolism. Xylose is
absorbed in a manner similar to glucose, utilizing carrier-
facilitated transport. This is in contrast to IgG, which is
absorbed non-selectively for approximately the first 24 h
after birth. It is possible that the addition of GF to the
formulations resulted in increased maturation of the
intestine, resulting in a loss of pinocytotic ability, but not
affecting carrier-mediated monosaccharide absorption.
Newborn calves readily absorbed the IgG
concentrate used in this study, and plasma IgG
concentrations at 24 h of age were indicative of successful
passive transfer. Results from this study indicate that 150 g
of IgG provided in one dose soon after birth is superior to
150 g of IgG fed in two doses 7 h apart. These data also
suggest that addition of a fraction of bovine plasma
containing elevated concentrations of IGF-I and TGF-_ to
the CS and CR formulation decreased IgG absorption in the
neonatal calf. Further studies are needed to determine the
biological mechanisms by which growth factors influence
intestinal immunoglobulin absorption in the neonatal calf.
Table 1. Formulation of experimental colostrum supplements (CS) and colostrum replacers (CR).
Ingredient (% of formula) LC1 LG HC HG
Ig concentrate 16.67 16.67 33.33 33.33
Dry fat blend2 35 35 35 35
Whey protein concentrate (75%) 10 5 5 0
Growth factor fraction 0 5 0 5
Whey 35.83 35.83 24.17 24.17
Premix3 2.5 2.5 2.5 2.5
1LC = 1.9 L of CS at 1 and 8 h; LG = 1.9 L of CS with GF at 1 and 8 h; HC = 1.9 L of CR at 1 h and 1.9 L of MR at 8
h; HG = 1.9 L of CR with GF at 1 h and MR at 8 h
2Dry fat blend containing 7% and 60% crude fat
3Premix contains vitamins and minerals to meet 1998 NRC requirements
Table 2. Composition of experimental colostrum supplements, colostrum replacers, and milk replacer.
Item1, % LC2 LG HC HG MR3
DM 96.8 93.6 95.5 93.6 97.1
CP 31.3 32.1 40.3 41.5 21.3
Ash 5.7 5.5 4.8 4.8 7.1
Fat 19.8 23.6 23.1 23.8 23.6
1Items are on a DM basis, except for DM
2LC = 1.9 L of CS at 1 and 8 h; LG = 1.9 L of CS with GF at 1 and 8 h; HC = 1.9 L of CR at 1 h and 1.9 L of MR at 8
h; HG = 1.9 L of CR with GF at 1 h and MR at 8 h
3MR = commercial milk replacer provided to calves in treatments HC and HG at 8 h of age
Table 3. Composition and analysis of serum fraction GF.
Item1 Value
DM, % 96.6
TP, % 93.24
Albumin, % 56.64
IgG, % 19.7
Ash, % 0.61
TGF-β1, ng/g 765
TGF-β2, ng/g 9
IGF-1, ng/g 1368
1Items are on a DM basis, except for DM
Table 4. Least squares means of treatment parameters for calves fed LC, LG, HC, HG and MC.
Item
Treatment1 Contrasts2
MC LC LG HC HG SE 1 2 3 4
No. calves 7 7 7 8 7 ... ... ... ... …
BW, kg 49.4 47.3 45.4 45.2 49.2 1.8 NS3 NS NS NS
IgG intake, g 282 150 150 150 150 9 0.001 NS NS NS
Protein intake, g 494 303 302 296 299 13 0.001 NS NS NS
Plasma IgG, g/L
    0 h 0 0 0 0 0 0 NS NS NS NS
    24 h 18.1 10.6 9.1 13.0 10.3 0.9 0.001 0.05 0.02 NS
    Change 0-24 h 18.1 10.6 9.1 13.0 10.3 0.9 0.001 0.05 0.02 NS
AEA4 % 29 30 24 35 30 2 NS 0.02 0.03 0.07
FPT5, % 0 42 57 0 28 14 0.06 0.02 NS NS
Plasma protein, g/L
    0 h 4.75 4.62 4.37 4.57 4.51 0.15 NS NS NS NS
    24 h 6.12 5.02 5.20 5.24 4.91 0.17 0.001 NS NS NS
    Change 0-24 h 1.37 0.40 0.86 0.61 0.40 0.15 0.001 NS NS 0.06
Hematocrit, %
    0 h 40.14 42.57 33.14 37.62 39.28 2.62 NS NS 0.09 0.06
    24 h6 33.19 33.65 29.85 34.76 36.21 1.58 NS 0.02 NS 0.01
    Change 0-24 h6 -5.12 -4.66 -8.45 -3.55 -2.10 1.58 NS 0.02 NS 0.01
1MC = 1.9 L of maternal colostrum at 1 and 8 h; LC = 1.9 L of CS at 1 and 8 h; LG = 1.9 L of CS with GF at 1 and 8 h;
HC = 1.9 L of CR at 1 h and 1.9 L of MR at 8 h; HG = 1.9 L of CR with GF at 1 h and MR at 8 h
2Contrasts: 1 = MC vs. CR; 2 = Low vs. High; 3 = 5% GF vs. 0% GF; 4 = LG vs. HG
3P > 0.10
4Apparent efficiency of absorption, calculated as plasma IgG (g/L) × BW (kg) × 9% ÷IgG intake (g)
5Failure of passive transfer (IgG < 10 g/L)
6Covariate adjusted
Table 5. Least squares means for xylose absorption in calves fed HG, HC, and MC.
Item
Treatment1 Contrasts2
MC HC HG SE 1 2
No. calves 5 6 5 ... ... ...
Xylose absorption, mg/dl
    0 h 16.56 15.22 15.89 0.56 NS3 NS
    2 h 71.55 55.97 60.76 9.0 NS NS
    Change 0-2 h 54.98 40.74 44.87 8.9 NS NS
1MC = 1.9 L of maternal colostrum at 1 and 8 h; HC = 1.9 L of CR at 1 h and 1.9 L of MR at 8 h; HG = 1.9 L of CR with
GF at 1 h and MR at 8 h
2Contrasts: 1 = MC vs. CR; 2 = 5% GF vs. 0% GF     3P > 0.10
